

MATERIAL SUPLEMENTARIO

Anexo 1. Patrones de resistencia en cepas E.coli de urocultivos realizados en el Instituto Nacional Materno Perinatal de Lima, Perú 2018

Perfil de resistencia		Total	Total (%)	Hospitalario N (%)	Ambulatorio (%)	BLEE
I	Q-Amg-Amc-Cef-Fos-Nit-Sxt	2	2/291 (0,69)	0	2 (100)	2
II	Q-Amg-Amc-Cef-Fos-Nit	2	2/291 (0,69)	0	2 (100)	1
	Q-Amg-Amc-Cef-Fos-Sxt	4	4/291 (1,37)	1 (25)	3 (75)	4
	Q-Amg-Amc-Cef-Nit-Sxt	3	3/291 (1,03)	0	3(100)	0
	Q-Amg-Amc-Fos-Nit-Sxt	1	1/291 (0,34)	0	1 (100)	0
	Q-Amc-Cef-Fos-Nit-Sxt	3	3/291 (1,03)	2(66,7)	1 (33,3)	2
III	Q-Amg-Amc-Cef-Fos	1	1/291 (0,34)	0	1 (100)	1
	Q-Amg-Amc-Cef-Nit	4	4/291 (1,37)	1 (25)	3 (75)	3
	Q-Amg-Amc-Fos-Sxt	1	1/291 (0,34)	0	1 (100)	0
	Q-Amg-Amc-Cef-Sxt	13	13/291 (4,47)	1 (7,7)	12 (92,3)	9
	Q-Amg-Cef-Nit-Sxt	1	1/291 (0,34)	1 (100)	0	1
	Q-Amg-Cef-Fos-sxt	5	5/291 (1,72)	2 (40)	3 (60)	4
	Q-Amc-Cef-Fos-Sxt	5	5/291 (1,72)	0	5 (100)	3
	Q-Amc-Cef-Nit-Sxt	8	8/291 (2,75)	2 (25)	6 (75)	4
IV	Q-Amg-Amc-Cef	7	7/291 (2,41)	2 (28,6)	5 (71,4)	7
	Q-Amg-Amc-Nit	1	1/291 (0,34)	0	1 (100)	0
	Q-Amg-Amc-Sxt	4	4/291 (1,37)	1 (25)	3 (75)	0
	Q-Amg-Cef-Fos	4	4/291 (1,37)	1 (25)	3 (75)	4
	Q-Amg-Cef-Nit	1	1/291 (0,34)	1 (100)	0	1
	Q-Amg-Cef-Sxt	11	11/291 (3,78)	3 (27,3)	8 (72,7)	9
	Q-Amg-Nit-Sxt	2	2/291(0,69)	0	2 (100)	0
	Q-Amc-Cef-Fos	2	2/291(0,69)	0	2 (100)	2
	Q-Amc-Cef-Nit	1	1/291 (0,34)	0	1 (100)	0
	Q-Amc-Cef-Sxt	15	15/291 (5,15)	6 (40)	9 (60)	7
	Q-Cef-Fos-Nit	1	1/291 (0,34)	0	1 (100)	1
	Q-Cef-Fos-Sxt	4	4/291 (1,37)	0	4 (100)	2
	Q-Cef-Nit-Sxt	2	2/291 (0,69)	0	2 (100)	0
	Q-Fos-Nit-Sxt	1	1/291 (0,34)	0	1 (100)	0
	Amc-Cef-Fos-Nit	1	1/291 (0,34)	0	1 (100)	0
	Amc-Cef-Nit-Sxt	1	1/291 (0,34)	1(100)	0	0
V	Q-Amc-Cef	6	6/291 (2,06)	0	6 (100)	0
	Q-Amc-Sxt	6	6/291 (2,06)	1 (16,7)	5 (83,3)	0
	Q-Amg-Cef	1	1/291 (0,34)	0	1 (100)	0
	Q-Amg-Sxt	4	4/291 (1,37)	0	4 (100)	4
	Q-Cef-Fos	2	2/291 (0,69)	0	2 (100)	1
	Q-Cef-Nit	2	2/291 (0,69)	1 (50)	1(50)	1
	Q-Cef-Sxt	19	19/291 (6,8)	8 (42,1)	11(59,9)	8
	Q-Fos-Nit	1	1/291 (0,34)	0	1 (100)	0
	Q-Nit-Sxt	3	3/291 (1,03)	1 (33,3)	2 (66,7)	0
	Amg-Cef-Sxt	1	1/291 (0,34)	0	1 (100)	0
	Amc-Cef-Sxt	1	1/291 (0,34)	0	1 (100)	0
	Cef-Nit-Sxt	1	1/291 (0,34)	1 (100)	0	0
VI	Q-Amg	7	7/291 (2,41)	2 (28,6)	5(71,4)	0
	Q-Amc	4	4/291 (1,37)	2 (50)	2 (50)	0
	Q-Cef	21	21/291 (7,5)	2 (9,5)	19 (90,5)	6
	Q-Sxt	27	27/291 (9,6)	2 (7,4)	25 (92,6)	0
	Q-Nit	6	6/291 (2,06)	0	6 (100)	0
	Amc-Cef	2	2/291 (0,69)	1 (50)	1 (50)	0
	Amc-Sxt	1	1/291 (0,34)	0	1 (100)	0
	Cef-Sxt	1	1/291 (0,34)	0	1 (100)	0
	Nit-Sxt	1	1/291 (0,34)	0	1 (100)	0
VII	Q	46	46/291 (16,37)	4 (8,7)	42 (91,30)	0
	Amc	1	1/291 (0,34)	0	1 (100)	0
	Sxt	5	5/291 (1,72)	1 (20)	4 (80)	0
VIII	Pansensible	11	11/291 (3,78)			

BLEE, Beta-lactamasas de espectro extendido; Q, quinolonas; Amg, aminoglucósidos; Amc, amoxicilina-clavulánico; Cef, cefalosporinas; Nit, nitrofurantoin; Sxt, trimethoprim- sulfametoxazole; Fos, fosfomicina.